Athenex Inc (NASDAQ:ATNX) CEO Johnson Yiu Nam Lau Purchases 10,000 Shares

Athenex Inc (NASDAQ:ATNX) CEO Johnson Yiu Nam Lau acquired 10,000 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was acquired at an average price of $14.90 per share, for a total transaction of $149,000.00. Following the completion of the purchase, the chief executive officer now owns 3,031,959 shares of the company’s stock, valued at approximately $45,176,189.10. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Athenex stock traded down $0.40 on Thursday, reaching $14.82. 357,277 shares of the stock were exchanged, compared to its average volume of 486,927. Athenex Inc has a 1-year low of $9.38 and a 1-year high of $21.11. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.62 and a quick ratio of 2.33. The stock’s fifty day simple moving average is $18.44. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -10.29 and a beta of -0.30.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.44). Athenex had a negative net margin of 161.17% and a negative return on equity of 85.39%. The business had revenue of $22.20 million for the quarter, compared to analyst estimates of $18.15 million. On average, sell-side analysts anticipate that Athenex Inc will post -1.92 earnings per share for the current fiscal year.



A number of institutional investors and hedge funds have recently modified their holdings of ATNX. BlackRock Inc. grew its position in Athenex by 26.0% during the second quarter. BlackRock Inc. now owns 4,508,787 shares of the company’s stock worth $89,275,000 after buying an additional 930,726 shares during the period. Vanguard Group Inc. grew its position in Athenex by 33.9% during the second quarter. Vanguard Group Inc. now owns 2,832,668 shares of the company’s stock worth $56,087,000 after buying an additional 717,109 shares during the period. Nuveen Asset Management LLC acquired a new position in Athenex during the second quarter worth about $5,848,000. Emory University acquired a new position in Athenex during the first quarter worth about $2,312,000. Finally, Point72 Asset Management L.P. acquired a new position in Athenex during the second quarter worth about $2,818,000. Institutional investors own 26.93% of the company’s stock.

A number of research firms have commented on ATNX. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price objective (up from $29.00) on shares of Athenex in a research note on Tuesday, June 25th. Zacks Investment Research lowered shares of Athenex from a “hold” rating to a “sell” rating in a research note on Tuesday, July 9th. Oppenheimer began coverage on shares of Athenex in a research note on Thursday, May 2nd. They issued an “outperform” rating and a $20.00 price objective on the stock. BidaskClub lowered shares of Athenex from a “buy” rating to a “hold” rating in a research note on Friday, July 19th. Finally, SunTrust Banks boosted their price target on shares of Athenex to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $23.83.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Recommended Story: How does inflation affect different investments?

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.